Stockreport

Entero Therapeutics' Chairman and CEO James Sapirstein Provides Business Update with Focus on Latiglutenase Development Program [Yahoo! Finance]

Entero Therapeutics Inc.  (ENTO) 
PDF biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today released a letter from James Sapi [Read more]